Get started
Denali Therapeutics Inc.Denali Therapeutics Inc.Denali Therapeutics Inc.

Denali Therapeutics Inc.

No trades
No trades
OverviewFinancialsDocumentsNewsCommunityTechnicalsForecastsSeasonalsOptionsETFs
Full chart
Full chart

Compare with Denali Therapeutics Inc.



Key stats


Market capitalization
‪3.89 B‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−2.84 USD
Net income (FY)
‪−512.54 M‬ USD
Revenue (FY)
0.00 USD
Shares float
‪149.78 M‬
Beta (1Y)
1.49

Latest earnings


Last report date
Aug 6, 2026
Report period
Q2 2026
EPS
−0.68 USD
Revenue
‪3.60 M‬ USD
Earnings call summary

AVLAYAH's first full commercial quarter generated $3.6M in revenue, with strong physician and patient engagement and over 50% payer coverage. Cash reserves exceed $1.1B, supporting a robust pipeline and guidance for Q3 revenue of $10–12M.

Employees


Employees (FY)
503
Change (1Y)
+81+19.19%
Revenue / Employee (1Y)
0.00 USD
Net income / Employee (1Y)
‪−1.02 M‬ USD

Company info


Sector
Health Technology
Industry
Biotechnology
CEO
Ryan J. Watts
Website
denalitherapeutics.com
Headquarters
San Francisco
Founded
2013
IPO date
Dec 8, 2017
ISIN
US24823R1059
CUSIP
24823R105
FIGI
BBG008P7F869
Identifiers
ISIN US24823R1059
CFI code
ESVUFR
Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

News



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

ETFs holding the stock


IWM
iShares Russell 2000 Index Fund
Weight0.11%
Market value‪92.10 M‬
XBI
State Street SPDR S&P Biotech ETF
Weight0.80%
Market value‪86.11 M‬
VBK
Vanguard Morningstar Small-Cap Growth ETF
Weight0.09%
Market value‪41.33 M‬
VXF
Vanguard Extended Market ETF
Weight0.04%
Market value‪39.93 M‬
IWN
iShares Russell 2000 Value ETF
Weight0.22%
Market value‪31.78 M‬
TCAF
T. Rowe Price Capital Appreciation Equity ETF
Weight0.37%
Market value‪30.74 M‬
IBB
iShares Biotechnology ETF
Weight0.26%
Market value‪26.86 M‬
VTWO
Vanguard Russell 2000 ETF
Weight0.11%
Market value‪19.00 M‬
SCHA
Schwab U.S. Small-Cap ETF
Weight0.07%
Market value‪17.44 M‬
DFAS
Dimensional U.S. Small Cap ETF
Weight0.07%
Market value‪11.13 M‬
DFMC
U.S. Micro Cap Portfolio: ETF Class Shares
Weight0.13%
Market value‪10.49 M‬

Explore more ETFs 

Frequently asked questions


The current price of DNLI is 24.31 USD — it has decreased by −0.16% in the past 24 hours. Watch Denali Therapeutics Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Denali Therapeutics Inc. stocks are traded under the ticker DNLI.
DNLI stock has fallen by −3.03% compared to the previous week, the month change is a 7.14% rise, over the last year Denali Therapeutics Inc. has showed a 65.37% increase.
We've gathered analysts' opinions on Denali Therapeutics Inc. future price: according to them, DNLI price has a max estimate of 42.00 USD and a min estimate of 27.00 USD. Watch DNLI chart and read a more detailed Denali Therapeutics Inc. stock forecast: see what analysts think of Denali Therapeutics Inc. and suggest that you do with its stocks.
DNLI reached its all-time high on Dec 22, 2020 with the price of 93.94 USD, and its all-time low was 10.57 USD and was reached on Apr 7, 2025. View more price dynamics on DNLI chart.
See other stocks reaching their highest and lowest prices.
DNLI stock is 2.00% volatile and has beta coefficient of 1.49. Track Denali Therapeutics Inc. stock price on the chart and check out the list of the most volatile stocks — is Denali Therapeutics Inc. there?
Today Denali Therapeutics Inc. has the market capitalization of ‪3.89 B‬, it has increased by 1.73% over the last week.
Yes, you can track Denali Therapeutics Inc. financials in yearly and quarterly reports right on TradingView.
Denali Therapeutics Inc. is going to release the next earnings report on Nov 11, 2026. Keep track of upcoming events with our Earnings Calendar.
DNLI earnings for the last quarter are −0.68 USD per share, whereas the estimation was −0.51 USD resulting in a −32.54% surprise. The estimated earnings for the next quarter are −0.39 USD per share. See more details about Denali Therapeutics Inc. earnings.
Denali Therapeutics Inc. revenue for the last quarter amounts to ‪3.60 M‬ USD, despite the estimated figure of ‪2.15 M‬ USD. In the next quarter, revenue is expected to reach ‪12.31 M‬ USD.
DNLI net income for the last quarter is ‪−127.55 M‬ USD, while the quarter before that showed ‪−128.45 M‬ USD of net income which accounts for 0.00% change. Track more Denali Therapeutics Inc. financial stats to get the full picture.
No, DNLI doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Aug 19, 2026, the company has 503 employees. See our rating of the largest employees — is Denali Therapeutics Inc. on this list?
Like other stocks, DNLI shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Denali Therapeutics Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Denali Therapeutics Inc. technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Denali Therapeutics Inc. stock shows the buy signal. See more of Denali Therapeutics Inc. technicals for a more comprehensive analysis.